Goldenhar syndrome associated with prenatal maternal fluoxetine ingestion: Cause or coincidence?

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 88, Issue 7, 2010, Pages 582-585

  Farra, Chantal ^a   Yunis, Khalid ^a   Mikati, Mohammad ^a   Yazbeck, Nadine ^a   Majdalani, Marianne ^a   Awwad, Johnny ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Craniofacial malformations; Fluoxetine hydrochloride; Goldenhar; Oculo auriculo vertebral spectrum; Prozac; Serotonin

Indexed keywords

FLUOXETINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CASE REPORT; FACE ASYMMETRY; GOLDENHAR SYNDROME; HEART VENTRICLE SEPTUM DEFECT; HUMAN; MALE; MANDIBLE HYPOPLASIA; MICROTIA; NEWBORN; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RETINA MACULOPATHY; SCOLIOSIS; ADULT; CHEMICALLY INDUCED; CONGENITAL MALFORMATION; ENVIRONMENTAL EXPOSURE; FEMALE; PATHOLOGY; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FEMALE; FLUOXETINE; GOLDENHAR SYNDROME; HUMANS; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 77954710550     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20674     Document Type: Article

References (21)

1. Abusheika N, Salha O, Sharma V, et al. 2000. Monozygotic twinning and IVF/ICSI treatment: a report of 11 cases and review of literature. Hum Reprod Update 6:396-403.
2. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692.
3. Araneta MRG, Moore C, Olney RS, et al. 1997. Goldenhar syndrome among infants born in military hospitals to Gulf War veterans. Teratology 56:244-51.
4. Bérard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:8-27.
5. Chambers CD, Johnson KA, Dick LM, et al. 1996. Birth outcomes in pregnant women taking Fluoxetine. N Engl J Med 335:1010-1015. (Pubitemid 26338730)
6. Cullins SL, Pridjian G, Sutherland CM, 1994. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation (letter). JAMA 271:1905-1906. (Pubitemid 24177092)
7. Derbent M, Orun UA, Varan B, et al. 2005. A new syndrome within the oculo-auriculo-vertebral spectrum: microtia, atresia of the external auditory canal, vertebral anomaly, and complex cardiac defects. Clin Dysmorph 14:27-30. (Pubitemid 40189206)
8. Gorlin RJ, Cohen MM, Levin LS. 2001. Branchial arch and oro-acral disorders. In: Syndromes of the head and neck. 4th ed. New York: Oxford University Press. pp. 101-114.
9. Greene MF. 2007. Teratogenicity of SSRIs: serious concern or much ado about little? N Engl J Med 356(26):2732-2733.
10. Gustafson T, Toneby M. 1970. On the role of serotonin and acetylcholine in sea urchin morphogenesis. Exp Cell Res 62:102-117.
11. Kallen BA, Otterblad Olaussen P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant malformations. Birth Defects Res A Clin Mol Teratol 79:301-308.
12. Lauder JM, Moiseiwitsch J, Liu J, et al. 1994. Serotonin in development and pathophysiology. Brain lesions in the newborn. In: Lou HC, Griesen G, Larsen JF (eds). Alfred Benzon Symposium. 2nd ed. Copenhagen: Munksgaard. pp. 60-73.
13. Lessick M, Vasa R, Israel J, et al. 1991. Severe manifestations of oculoauriculovertebral spectrum in a cocaine exposed infant. J Med Genet 28:803-804. (Pubitemid 21922555)
14. Louik C, Lin AE, Werler MM, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683. (Pubitemid 47001035)
15. Marden PM, Smith DW, McDonald MI, et al. 1964. Congenital anomalies in the newborn infant, including minor variations. Pediatrics 64:358-371.
16. Moiseiwitsch J. 2000. The role of serotonin and neurotrasmitters during craniofacial development. Crit Rev Oral Biol Med 11: 230-239.
17. Moiseiwitsch JRD, Lauder IM. 1997. Regulation of gene expression in cultured embryonic mouse mandibular mesenchyme by serotonin antagonists. Anat Embryol 195:71-78.
18. Moiseiwitsch JRD, Raymond IR, Tamir H, et al. 1998. Regulation by serotonin of tooth-germ morphogenesis and gene expression in mouse mandibular explant cultures. Arch Oral Biol 43:789-800.
19. Pastuszak A, Schick-Boschetto B, Zuber C, et al. 1993. Pregnancy outcome following first-trimester exposure to Fluoxetine (Prozac). J Am Med Assoc 269:2246-2248. (Pubitemid 23120281)
20. Shuey DL, Sadler TW, Tamir H, et al. 1993. Serotonin and morphogenesis. II. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol 187:75-85.
21. Wogelius P, Nørgaard M, Gislum M, et al. 2006. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17:701-704.